Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

91.35 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
52 53 Next >
Gilead's Chronic Hepatitis Delta Infection Treatment Shows Sustained Efficacy, Safety Profile At Two Years
Gilead Sciences Inc (NASDAQ: GILD) announced Week 96 results from the MYR301 Phase 3 clinical trial evaluating bulevirtide for  
Via Benzinga
Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks
From Gilead Sciences, Inc.
Via Business Wire
$1000 Invested In This Stock 20 Years Ago Would Be Worth $11,000 Today
Via Benzinga
AbTherx Announces License Agreement with Gilead
Via ACCESSWIRE
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Via Benzinga
Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan
From Gilead Sciences, Inc.
Via Business Wire
Alleged Industrial Espionage Makes an Interesting Story
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment. 
Via The Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Gilead and Regeneron Pharmaceuticals both had triple-digit percentage growth over the past decade. 
Via The Motley Fool
Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death
A patient died in Arcellx's multiple myeloma drug study. But the underlying factors are complex. 
Via Investor's Business Daily
Arcellx's Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock Falls
The FDA has put a clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 clinical program for CART-ddBCMA investigational new drug for  
Via Benzinga
How to Retire Rich: Biotech Stocks Edition
Thanks to its enormous and practically permanent relevancies, the biotech sector offers a great avenue for retirement planning stocks. 
Via InvestorPlace
Alcoholic Hepatitis Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Durect Corporation, Novartis, Intercept Pharma, Gilead Sciences
Via AB Newswire
Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023
From Gilead Sciences, Inc.
Via Business Wire
5 Stocks to Buy With Explosive 500% Potential
Take advantage of a bullish change in investor sentiment with these five stocks to buy for 500% upside potential. 
Via InvestorPlace
2022 R&D Spending and Intensity Benchmarks
VIRGINIA BEACH, Va. - June 12, 2023 - PRLog -- According to a newly released study from Schonfeld & Associates, Inc., R&D Ratios & Budgets, the pharmaceutical industry continued to be the biggest R&D... 
Via PRLog
Topics Supply Chain
Exposures Supply Chain
Is the Biotech Industry (IBB) Poised For A Major Breakout?
The current consolidation in the IBB signals a potential breakout might be looming as key moving averages have converged within a contracted price range. 
Via MarketBeat
Topics ETFs
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
2 Top Biotech Stocks to Buy in June
Both companies have solid therapy franchises and continue to expand their horizons. 
Via The Motley Fool
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action
FN Media Group Presents USA News Group News Commentary Vancouver, BC – June 8, 2023 – USA News Group – By utilizing newly developed novel mechanisms, biotech researchers and scientists are making... 
Via FinancialNewsMedia
3 Biotech Stocks That Could Skyrocket in the Next 12 Months
These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months. 
Via InvestorPlace
Kite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Crashes
ImmunoGen and Day One gained Monday on their updates at a cancer treatment conference. 
Via Investor's Business Daily
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study
From Gilead Sciences, Inc.
Via Business Wire
Biotechs Zeroing In on Developing Breakthrough Therapeutics for Metastatic Breast Cancer
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NASDAQ:RAIN),(NASDAQ:CNSP),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
3 Dividend Stocks You Can Buy Without Any Hesitation
The choices are easy with these stocks. 
Via The Motley Fool
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
3 Undervalued Biotech Stocks to Buy Before They Blast Off
Fundamental analysis makes these three undervalued biotech stocks to buy plus they have other catalysts that make them compelling. 
Via InvestorPlace
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
52 53 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.